PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Therapy-related myeloid neoplasms: when genetics and environment collide.

Abstract Therapy-related myeloid neoplasms (t-MN) arise as a late effect of chemotherapy and/or radiation administered for a primary condition, typically a malignant disease, solid organ transplant or autoimmune disease. Survival is measured in months, not years, making t-MN one of the most aggressive and lethal cancers. In this Review, we discuss recent developments that reframe our understanding of the genetic and environmental aetiology of t-MN. Emerging data are illuminating who is at highest risk of developing t-MN, why t-MN are chemoresistant and how we may use this information to treat and ultimately prevent this lethal disease.
PMID
Related Publications

Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.

Therapy-related myelodysplasia and acute myeloid leukemia.

Incidence and susceptibility to therapy-related myeloid neoplasms.

Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.

Therapy-related myeloid neoplasms in 39 Korean patients: a single institution experience.

Authors

Mayor MeshTerms

Chromosome Aberrations

Gene-Environment Interaction

Keywords
Journal Title nature reviews. cancer
Publication Year Start




PMID- 28835720
OWN - NLM
STAT- MEDLINE
DA  - 20170824
DCOM- 20170912
LR  - 20170912
IS  - 1474-1768 (Electronic)
IS  - 1474-175X (Linking)
VI  - 17
IP  - 9
DP  - 2017 Aug 24
TI  - Therapy-related myeloid neoplasms: when genetics and environment collide.
PG  - 513-527
LID - 10.1038/nrc.2017.60 [doi]
AB  - Therapy-related myeloid neoplasms (t-MN) arise as a late effect of chemotherapy
      and/or radiation administered for a primary condition, typically a malignant
      disease, solid organ transplant or autoimmune disease. Survival is measured in
      months, not years, making t-MN one of the most aggressive and lethal cancers. In 
      this Review, we discuss recent developments that reframe our understanding of the
      genetic and environmental aetiology of t-MN. Emerging data are illuminating who
      is at highest risk of developing t-MN, why t-MN are chemoresistant and how we may
      use this information to treat and ultimately prevent this lethal disease.
FAU - McNerney, Megan E
AU  - McNerney ME
AD  - Department of Pathology and the Department of Pediatrics, The University of
      Chicago, Chicago, Illinois 60637, USA.
AD  - University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
      60637, USA.
FAU - Godley, Lucy A
AU  - Godley LA
AD  - Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA.
AD  - University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
      60637, USA.
FAU - Le Beau, Michelle M
AU  - Le Beau MM
AD  - Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA.
AD  - University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
      60637, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Nat Rev Cancer
JT  - Nature reviews. Cancer
JID - 101124168
RN  - 0 (Antineoplastic Agents, Alkylating)
SB  - IM
MH  - Antineoplastic Agents, Alkylating/adverse effects
MH  - Bone Marrow Cells
MH  - *Chromosome Aberrations
MH  - Chromosomes, Human, Pair 5
MH  - Chromosomes, Human, Pair 7
MH  - Clone Cells/physiology
MH  - *Gene-Environment Interaction
MH  - Genetic Predisposition to Disease
MH  - Hematopoiesis
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*etiology/therapy
MH  - Mutation
MH  - Myelodysplastic Syndromes/*etiology/therapy
MH  - Neoplasms, Second Primary/*etiology/therapy
MH  - Prognosis
MH  - Radiation Exposure/adverse effects
MH  - Risk Factors
EDAT- 2017/08/25 06:00
MHDA- 2017/09/13 06:00
CRDT- 2017/08/25 06:00
AID - nrc.2017.60 [pii]
AID - 10.1038/nrc.2017.60 [doi]
PST - ppublish
SO  - Nat Rev Cancer. 2017 Aug 24;17(9):513-527. doi: 10.1038/nrc.2017.60.